Entrada Therapeutics/$TRDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Ticker
$TRDA
Sector
Primary listing
Employees
152
Headquarters
Website
TRDA Metrics
BasicAdvanced
$257m
-
-$4.00
-0.09
-
Price and volume
Market cap
$257m
Beta
-0.09
52-week high
$16.45
52-week low
$4.93
Average daily volume
430k
Financial strength
Current ratio
13.903
Quick ratio
13.397
Long term debt to equity
16.787
Total debt to equity
18.368
Profitability
EBITDA (TTM)
-172.556
Gross margin (TTM)
-2,366.87%
Net profit margin (TTM)
-2,895.05%
Operating margin (TTM)
-3,076.18%
Effective tax rate (TTM)
-0.58%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-26.84%
Return on equity (TTM)
-48.28%
Valuation
Price to revenue (TTM)
51.573
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-2.248
Free cash flow yield (TTM)
-44.49%
Free cash flow per share (TTM)
-3.167
Growth
Revenue change (TTM)
-96.67%
Earnings per share change (TTM)
-761.41%
3-year revenue growth (CAGR)
-38.98%
3-year earnings per share growth (CAGR)
16.53%
What the Analysts think about TRDA
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
TRDA Financial Performance
Revenues and expenses
TRDA Earnings Performance
Company profitability
TRDA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $257M as of May 13, 2026.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 0 as of May 13, 2026.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of May 13, 2026.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of -0.09. This means that it has an inverse relation to market volatility.